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Abstract
Pediatric brain cancer patients are at a
high risk for radiation-induced cognitive
impairment due to white matter changes in
the brain. Half of six-month radiotherapy
survivors develop significant changes
in white matter. Previous research has
shown that a mouse model can be used
to show similar cognitive and behavioral
deficits in human patients. The purpose of
this work is to evaluate the effectiveness
of two drug therapies, Donepezil and
3,3-Diindolylmethane (DIM), that could be
used to either protect the brain from radiation
injury or cure the cognitive injury and
behavioral deficits that result from wholebrain irradiation. This project consisted
of two parts: administration of Donepezil
postradiation as a symptomatic cure and
administration of DIM before radiation as
a protectant. The mice received 30 gray
whole brain radiation, and their behavioral
changes were measured at 4 and 8 weeks
postradiation. Behavioral changes were
observed using two tests: the Open Field Test
and Marble Burying Test. These tests were
to see if the treated mice would have results
closer to the healthy baselines established
in previous research. From our data, we
observed Donepezil to be an ineffective form
of therapy, as the deficits did not improve.
However, DIM has shown to be a promising
protectant drug therapy, as the behavioral data
is closer to the results of a healthy control.
This research validates the potential of DIM
to be used as a radio protectant in preventing
both radiation injury and any cognitive
deficits from following.

Keywords
cancer, radiation, mice, brain, behavior, drug
therapy, cognitive injury, radiation oncology

Over the past four years, my work under Dr.
Carlos Perez-Torres has focused on evaluating the
neurocognitive effects of radiation on the brain using
a mouse model. During my freshman year, our first
goal was to identify when late cognitive effects
are seen in the brain and understand the extent of
damage induced from radiation. We also wanted to
find an appropriate radiation dosage that would allow
us to model brain damage clearly in a mouse.
We started off by radiating female mice
approximately 5–6 weeks old, mimicking a human
pediatric brain, with five different radiation dosages
of 10, 15, 20, 25, and 30 gray onetime treatment,
by use of a linear accelerator. For comparison, the
standard therapy dosage for humans ranges from
about 14 to 24 Gy for brain metastases (Timmerman,
2008). Then, we monitored the effects of radiation on
these brains at different time points postradiation by
euthanizing different groups of mice at 1 hour or 4,
8, 12, or 16 weeks. We analyzed the damage to the
brain by using immunohistochemistry to stain brain
tissue for different kinds of damage. Results showed
that 30 Gy was the dosage most effective in showing
consistent damage and that damage was the worst at
8 and 16 weeks postradiation.
Next, we investigated the differences between male
and female mice in their response to radiation.
Initially, the assumption supported by other research
showed that female mice were more susceptible to
radiation than male mice. So, females would make
better models, as their sensitivity would show the
effects of injury quite clearly. However, we could
not assume that what we were seeing in female
mice would be exactly what we might see in male
mice. To do this, we radiated both female and male
mice with the same dosages of radiation and then
used immunohistochemistry to compare the injury
between the two sexes. We found that females and
males showed radiation injury in different ways. The
males showed more injury at a later time point, while
the females were more susceptible to the effects of
radiation earlier on.
After establishing reliable methods where we could
consistently model radiation damage in mice, we
wanted to further explore the extent of cognitive
damage. The cognitive damage is best observed
as behavioral changes. Our primary question was
whether mice that received brain radiation developed
the same cognitive and behavioral changes as seen in
human patients.
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GOALS AND AIMS OF THE PROJECT

In order to track the behavioral changes, we first
had to pick behavioral tests to accurately and
consistently show these changes. The Open Field
and Marble Burying Tests were chosen for their
ability to measure normal mouse behaviors, anxiety,
and cognitive ability. Both behavioral tests showed
a significant cognitive decline in the mice after
receiving radiation. The behavioral impairments
increased with time, as supported by pathology.
All of this work has led to my final senior project:
developing drug therapies for cognitive damage in
mice following brain radiation. The purpose of this
project was to investigate whether drug therapies,
such as Donepezil and 3,3-Diindolylmethane (DIM),
can be used in mice to protect from or reverse the
cognitive damage that results from brain radiation.

BACKGROUND
Cancer today is considered one of the leading causes
of death around the world, especially for children.
Brain cancer is among one of those top cancers
causing death. For adults, recovery from brain
cancer is uncommon because of how aggressive the
cancer can be. The survival rate for malignant brain
tumors in adults is only 35%, while in children the
survival rate is 74% (“Quick Brain Tumor Facts,”
n.d.). Radiation is commonly used as an effective
form of therapy when treating brain tumors. But like
other treatments such as chemotherapy and surgery,
radiation comes with risks.
Pediatric brain cancer patients who survive radiation
therapy are at a high risk for radiation-induced
cognitive impairment in healthy tissue surrounding
the tumor due to white matter changes in the brain.
Unfortunately, about half of six-month radiotherapy
survivors develop significant changes in white matter,
potentially leading to significant cognitive changes
and impairment. Some of the side effects observed
have been learning deficits, a decrease in IQ, or
different neurocognitive effects. These side effects
are rarely seen in adults, because most adults do
not survive long enough after being diagnosed and
treated with radiation (Attia et al., 2014). To further
investigate these effects, a mouse model of radiation
injury was developed to investigate if mice that
received brain radiation develop the same cognitive
and behavioral changes as seen in human patients.
When radiation doses are used for mice, higher
doses must be used, because mice tend to have a
higher resistance to the effects of radiation. It is also
important to keep in mind that humans and mice
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have differences in timing and amount of radiation
dosage. Human clinical patients are usually radiated
with about 2 Gy, five days a week. However, to
mimic that in mice would be extremely expensive
and time-consuming. So, mice are usually radiated
with a higher dose one time.
Mouse models can be used to show the changes in
the brain postradiation, using immunohistochemistry
to look for pathological changes and behavior tests
to observe changes in behavior. In human patients,
behavioral changes include increased anxiety, loss of
memory, and a decrease in IQ. Increased anxiety and
memory loss are also behaviors that can be measured
and observed in mice using the Open Field Test and
the Marble Burying Test.
Results showed that brain radiation does cause
behavioral changes, and this injury can be modeled
in mice to show significant impairments. From
a pathology standpoint, radiation of healthy
brain tissue resulted in specific changes in white
matter consisting of large holes, cell death, and
inflammatory responses. This pathology produced
deficits that become more pronounced over time, as
supported by pathology and behavior tests.
In order to protect from or treat radiation damage
of healthy tissue, two drug therapies were
chosen to test—Donepezil and DIM. Donepezil,
a cognition-enhancing drug used to improve
memory and attention in Alzheimer’s patients, is a
central acetylcholinerase inhibitor that is injected
intraperitonealy (“Donepezil,” n.d.). It is a drug
therapy that focuses on treating the symptoms but
cannot cure the underlying disease. Side effects
include nausea, vomiting, diarrhea, cramps, weight
loss, and dizziness. DIM is a chemical naturally
formed in the body by breaking down cruciferous
vegetables such as broccoli, cauliflower, and cabbage
and is thought to possibly be a protectant from
cancer. DIM is a fat-soluble drug that is able to
cross the blood-brain barrier, which is an essential
characteristic for this therapy (“Diindolylmethane,”
n.d.). It is also injected intraperitonealy. Previous
literature has proven its use as a protection from
radiation damage to skin (Fan, 2013). The only
known side effects of the drug are that is can
make hormone-sensitive conditions worse, as
its mechanism of action is similar to estrogen
(“Diindolylmethane,” n.d.).
My project asks whether drug therapies can be used
in mice to reverse or protect from the cognitive
damage that results from brain radiation. My first

hypothesis is that Donepezil can be used to treat and
reverse the effects of radiation injury and cognitive
damage, and my second hypothesis is that DIM can
be used as a radioprotectant.

MATERIALS AND METHODS
In the previous behavior experiments that did not use
a drug therapy, groups of five 4–5-week-old female
Balb-c mice were irradiated with 30 Gy whole-brain
radiation using an X-RAD 320 (a Cabinated radiator).
Before radiation, the mass of each mouse was
recorded in order to monitor its health. If the mouse
lost too much weight, then it was euthanized. A
control group that received no radiation was initially
tested to set a baseline for the cognitive abilities and
behavior patterns of a healthy mouse. After radiation,
mice underwent behavior tests at three time points:
4, 8, and 16 weeks. As previously mentioned, the
behavior tests chosen were the Open Field and
Marble Burying Tests.
In the Open Field Test, the mouse is placed in an
artificially designed field. The field consists of a 40by 40-inch plastic box with opaque walls. A camera
was hung on an apparatus over the top of the field to
monitor its movements, as shown in Figure 1a. The
mouse was placed in the center of the field and allowed
to freely roam for 20 minutes. Controls (mice not
treated with radiation) spent an even amount of time on
the inside, outside, corners, and middle of the field with
a high level of ambulation. Mice that showed cognitive
impairments postradiation spent more time on the
outside of the field and increased ambulation indicating
higher anxiety. Video analysis software with a Matlab
code was used to analyze the data.

For this project the same procedure was followed
exactly, only with the addition of drug therapies. In
the first experiment Donepezil was used. Starting
right after radiation, 5 mg/ml or 50 mg/kg of body
weight of Donepezil was administered five times

a week intraperitonealy to try to treat the radiation
damage. After radiation and during Donepezil
treatments, at 4 weeks and 8 weeks postradiation the
mouse underwent both the Open Field Test and the
Marble Burying Test. In the second experiment, 5 mg/
ml of DIM was administered 30–40 minutes before
radiation. The allotted time was to allow the drug to
spread throughout the body and cross the blood-brain
barrier. The mice were also tested at 4 and 8 weeks
postradiation with the behavior tests. The sample size
for the controls was 13, mice treated with Donepezil
was 5, and mice treated with DIM was 7.
Qualitative observations were taken throughout the
entirety of the experiments, and quantitative data
was recorded and analyzed by a one-way ANOVA
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In the Marble Burying Test, 15 black nonshiny
marbles were placed in a 3-by-5 grid in a mouse cage
with extra bedding, as shown in Figure 1b. Mice
were placed in the center of the cage and allowed to
bury and move freely for 20 minutes. At the end of
the 20 minutes, the number of marbles buried was
counted. If a marble was at least 50% covered by the
bedding, it was counted as buried. Control groups
were used to set a baseline range of how many
marbles a healthy mouse buried (11 marbles) to use
as comparison. Mice postradiation with cognitive
impairments buried significantly fewer marbles.

Figure 1. (A) Open Field Test apparatus. A mouse is
dropped into the center of the field and allowed to move
freely for 20 minutes. Movements of the mouse are tracked
with an overhanging camera and analyzed with a Matlab
software. (B) Marble Burying Test apparatus. A mouse is
dropped into a cage with 15 marbles (3 rows of 5). Each
mouse is given 20 minutes to bury the marbles. Normal
behavior of a healthy mouse is to bury around 11 marbles.

Dunnett and Bonferroni statistical analysis. Averages
of thigmotaxis and ambulation were compared, as
were the medians of the number of marbles buried.
The significant p-value chosen for difference between
groups was 0.05.

RESULTS
From the Matlab code analyzing the video of the
Open Field Test, a heat map was produced in one
image and a line trace of all of the movements
of the mouse during the 20 minutes in the open
field in another image. For the images produced

following the line of movement for the mouse, the
image contains two red boxes: one to differentiate
what was considered the inner quadrant and the
other to differentiate what was considered the
outer quadrant. This distinction was important
in analyzing thigmotaxis, a ratio of the time the
mouse spent on the outside divided by the total time.
Thigmotaxis is a useful measure of anxiety, as an
increased thigmotaxis is associated with increased
anxiety in those mice with cognitive impairments.
Figures 2a–c show the movement tracings of the
mice that received only radiation and no treatment,
and below that in Figures 2d–g are the movement
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Figure 2. Open Field Test Results. Images show the movements of a sample
mouse from each group represented by line tracings. The red boxes distinguish
the outer quadrant from the inner. These parameters were used to calculate
thigmotaxis, a ratio of time spent in the outside quadrant compared to total
time spent in both, a measure of mouse anxiety. 2a–c: Control group before
radiation and mice 4 and 8 weeks postradiation with no treatment. 2d–e:
Results of mice at 4 and 8 weeks postradiation treated with Donepezil. 2f–g:
Results of mice at 4 and 8 weeks postradiation treated with DIM.
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tracings of the mice that received Donepezil and
DIM treatments.
Based on the qualitative observations of these
movement tracings, the pictures of the mice treated
with Donepezil looked very similar to those of the
mice at 8 weeks that did not receive any treatment.
There are many lines pointing to the corners,
indicating that the mice spent more time on the
outside. At 4 weeks postradiation, the DIM pictures
looked similar to the 4 weeks with no treatment
pictures. However, the 8-week postradiation picture
looked more similar to the control that received no
radiation, as the movement appears to spread evenly
throughout the field.
To quantitatively analyze the Open Field Test data,
a statistical analysis was performed on the data
generated by the video Matlab code. Two important
measures were used to observe the differences
between the controls and the treated mice: average
total ambulation and average thigmotaxis. Figures
3 and 4 show the results of the Open Field Test
quantitative analysis.

Figure 4. Graph of average thigmotaxis. Data is presented
as mean with standard deviation. Thigmotaxis is a measure
of mouse anxiety and is calculated by dividing the total time
the mouse spent on the outer quadrant by the time spent
in both the outer and inner quadrants. ANOVA statistical
analysis showed that both groups at 4 weeks postradiation
treated with Donepezil or DIM were very statistically similar
to the control (p > 0.5). At 8 weeks postradiation, only the
group treated with DIM remained statistically similar to the
control (p > 0.05).
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In Figure 3, all the groups were statistically
significantly different from the control. Ideally, the
treatment groups would not be different from the
control, as the control is the baseline for a healthy
mouse. For average total ambulation, at 4 weeks
the treatments did not look different from the group
that did not receive a drug therapy. At 8 weeks, the
same amount of average ambulation was maintained
for both drug therapies. Donepezil appeared to be
getting closer to the control as time went on but
was not close enough to be statistically significant.
In Figure 4, the average thigmotaxis for both DIM
and Donepezil was not significantly different from
the control, indicating that anxiety might have been
decreased in the mice. However, by 8 weeks only
the DIM therapy maintained a statistically similar
thigmotaxis. So, it is possible that DIM, based on
this graph, could potentially have protected against
the radiation damage. Donepezil might have treated
a little bit of the damage, as observed in the average
total ambulation and average thigmotaxis, but the
therapy was not as effective as the deficits became
more pronounced. It was noticed that total average
ambulation might not be an accurate measure of
cognitive health, as some mice showed anxiety
through hyperactivity of increased movement, while
other mice showed anxiety through little or no
movement.

Figure 3. Graph of average total ambulation. Data is
presented as mean with standard deviation. Blue bars show
the control group as a comparison (n = 10) and the average
ambulation of mice who did not receive any treatment at 4
weeks postradiation and 8 weeks postradiation (n = 7). The
green bar shows mice that received DIM before radiation at
4 and 8 weeks postradiation (n = 7), and the red bars show
mice that received Donepezil treatments after radiation
(n = 5). ANOVA statistical analysis showed each group to
be statistically different from the control group.

DISCUSSION OF THE RESULTS
After collecting and analyzing all of the data from
the Open Field Test and the Marble Burying Test and
comparing it to the control groups that received no
treatment, it was apparent that individual variation
played a large role in the data. A larger sample size
could decrease this variation. Despite the noisy data,
the results shown did increase knowledge about what
kind of drug might work best to protect from or treat
the brain following radiation damage.
Figure 5. Graph of median number of marbles buried. Data
is presented as median with standard median absolute
deviation to reduce the effect of outliers. Mice treated with
DIM consistently buried more marbles than the group that
did not receive any drug therapy and the group treated
with Donepezil and was closest to the control median.

For the Marble Burying Test a significant number
of outliers were observed, as some groups were
consistent, while others contained many individuals
who varied greatly in the number of marbles they
buried. Therefore, the median was chosen as the
appropriate means of comparison between the
groups. Figure 5 shows the quantitative results of the
Marble Burying Test. The median absolute deviation
was used to draw error bars.
Figure 5 shows that DIM was the only effective
therapy that actually showed improvements from
the group that received no treatment. The use of
Donepezil actually worsened the effects of the
cognitive damage, as mice treated with this drug
performed much more poorly on the test. From a
qualitative perspective, it was noted that the mice
treated with DIM seemed to be much more mobile,
active, and healthy than the mice who did not
receive treatment. Those mice that were treated
with Donepezil were less mobile and active overall
and seemed sicker. Their overall manner was
more similar to the mice with significant cognitive
damage that received no treatment and did not bury
very many marbles.
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The Open Field Test showed that Donepezil might have
been a little effective at reducing anxiety initially but
was not strong enough to fight the worsening cognitive
impairment. DIM proved more promising long-term,
as it was able to produce a thigmotaxis similar to the
control, implying less anxiety.
The Marble Burying Test showed that DIM was
much better at lessening the cognitive impairment
of the radiation damage in the mice. It is important
to note that it did not protect the mice completely
from the damage but did possibly slow down its onset
or lessen the impairment. Donepezil did not show
improvements in cognitive ability.

CONCLUSION
Donepezil proved to be an ineffective form of
correction therapy, as it did not lessen the extent
of radiation damage to an effective degree. In the
Marble Burying Test, mice treated with Donepezil
buried a much smaller proportion of the marbles
than the control mice or even those mice who did
not receive any treatment. Donepezil might have
treated some damage initially as observed in the
Open Field Test, but the therapy was not effective as
time went on. However, both the Open Field Test and
the Marble Burying Test showed DIM to potentially
be an effective form of protective radiation therapy
for pediatric cancer patients who are at risk for
white-matter injury. In the Marble Burying Test,
mice treated with DIM buried more marbles than
the mice that received no treatment. The most
promising indicator of DIM’s potential or of drug
therapies whose mechanism is similar to DIM’s
was the qualitative observations. If DIM was able
to improve the overall health for most mice, then it
might be protecting from more radiation damage and
cognitive impairment than it shows quantitatively in
the behavior tests.
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